Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2000 September;52(3) > Minerva Urologica e Nefrologica 2000 September;52(3):147-50

CURRENT ISSUEMINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

  XVI CONGRESS DELLA SOCIETÀ ITALIANA DI NEFROLOGIA SEZIONE PIEMONTE-VALLE D’AOSTA
Castello di Rivoli, Rivoli (TO) October 10, 1998


Minerva Urologica e Nefrologica 2000 September;52(3):147-50

language: Italian

Pharmacoeconomics and hemodialysis. The role of iron in the treatment with erythropoietin

Navino C., David P., Cofano M. F., Borlandelli S., Verzetti G.

Azienda Maggiore della Carità - Novara U. O. Nefrologia e Dialisi


PDF  REPRINTS


Background. Although its efficacy is well known, the high economic cost of erythropoietin (EPO) raises the question of pharmacoeconomics in HD. An optimal Hb level with the lowest dosage of EPO seams to be correlated to the way of administration and an adequate iron supplementation.
Methods. The study evaluates the influence of iron supplementation on the control of EPO-related expenses.
Results. A serum ferritin level higher than 50 pg/ml in hemodialysis patients on chronic EPO therapy turned out to be adequate to keep an optimal Hb level. Our data show that this value, as far as pharmacoeconomic is concerned,is highly underestimated.
Conclusions. A higher i. v. iron supplementation correlates with a significant raise of serum ferritin level and saves on EPO-related expenses up to 1 million / per patient/per year.

top of page